Victhom Human Bionics http://www.victhom.com/ Victhom develops human bionic devices. Our objective is to improve the quality of life of people suffering from physical dysfunctions. en-ca Copyright 2007 daily Victhom discloses first quarter 2007 financial results http://www.victhom.com/en/nouvelle.php?id=92 Québec, Canada, May 11, 2007 - Victhom Human Bionics Inc., "Victhom" (TSX: VHB) today reported its 2007 first quarter financial results. First Quarter Highlights:Revenue reached $0.6 million for the first quarter, an increase of 7.4% over the same period last year;Net loss for the quarter decreased by $0.5 million or 18% to reach $2.3 million, compared to a net loss of $2.8 million in the first quarter of 2006;A public offering was completed for total gross proceeds of $12.4 million.Mr. Benoit Huet, President and CEO of Victhom, said: "During the first quarter, Victhom achieved two important milestones with the refocusing of the R&D activities and the conclusion of a $12.4 million public offering that considerably strengthens our balance sheet and demonstrates confidence in our business prospects". He mentioned that the addition of Mr. Nader Kameli as COO of the Neurobionix business unit is strengthening Victhom's expertise in the high-growth Neuromodulation industry. He also added that Dr. Guy Chamberland, Vice President, Clinical and Regulatory Affairs, has left the Company but will remain involved with Victhom as a consultant on a part-time basis.First Quarter ResultsFor the three-month period ended on March 31, 2007, the Company recorded revenues of $560,235 compared with $521,516 for the same period in 2006, representing an increase of $38,719 or 7.4%. The revenue increase compared to last year is attributable to the growth in nonrefundable advance royalty payments from our partner in the orthotics and prosthetics market. R&D expenses, before tax credits and grants, amounted to $1,984,179 for the three-month period ended on March 31, 2007, compared with $2,034,493 for the same period in 2006, representing a decrease of $50,314 or 2.5%. The decrease in R&D expenses is the result of the refocusing of the Neurobionix division R&D activities announced in January 2007, which resulted in a reduction in the number of employees. G&A expenses, net of non-cash stock-based compensation charges of $30,366, for the threemonth period ended on March 31, 2007, amounted to $603,977 compared with $807,928 for the same period in 2006, a decrease of $203,951 or 25%. The decrease is mainly due to a staff reduction in administrative functions and lower professional fees. Consolidated net loss for the quarter ended March 31, 2007, amounted to $2,254,308 compared to $2,757,567 for the same period in 2006, a decrease of $503,259 or 18%. The net loss, net of non-cash charges of $825,473, for the three-month period ended March 31, 2007, amounted to $1,428,835 compared to a net loss, net of non-cash charges of $905,461, for the same period in 2006, which amounted to $1,852,106, a decrease of $423,271 or 23%. The decrease in net loss, net of non-cash charges, is mainly the result of the lower development costs and G&A costs following the refocusing of R&D activities announced in January.Financial SituationAt March 31, 2007, the Company had cash and cash equivalents position of $17 million compared to $6.5 million as at December 31, 2006. The increase was mainly due to the issuance of shares in the financing completed in March for gross proceeds of $12.4 million. The Company believes that with its current financial resources it will have sufficient liquidity to support its cash flow requirements for at least the next 12 months. On March 31, 2007, the number of common shares outstanding totaled 87,922,263 while 4,241,876 options were granted under the stock option plan and 25,964,942 share purchase warrants are in circulation pursuant to past unit offerings. The outstanding options and share purchase warrants are exercisable respectively at a weighted average exercise price of $0.98 and $0.76 per share. About VicthomVicthom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix business unit focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix business unit develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics (or "O&P") market. Victhom's technologies and products are supported by a broad suite of intellectual property, including a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks, worldwide. Victhom has established a comprehensive process to ensure the protection of its intellectual property, pursuing filings for relevant discoveries and improvements.FORWARD-LOOKING STATEMENTSSome of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.- 30 -Source: Victhom Human Bionics Inc.For more information: Normand RivardVice President & CFOVicthom Human Bionics Inc.Tel.: (418) 872-5665, ext. 103Fax: (418) 872-6926normand.rivard@victhom.comwww.victhom.com

Québec, Canada, May 11, 2007 - Victhom Human Bionics Inc., "Victhom" (TSX: VHB) today reported its 2007 first quarter financial results. First Quarter Highlights:

  • Revenue reached $0.6 million for the first quarter, an increase of 7.4% over the same period last year;
  • Net loss for the quarter decreased by $0.5 million or 18% to reach $2.3 million, compared to a net loss of $2.8 million in the first quarter of 2006;
  • A public offering was completed for total gross proceeds of $12.4 million.

Mr. Benoit Huet, President and CEO of Victhom, said: "During the first quarter, Victhom achieved two important milestones with the refocusing of the R&D activities and the conclusion of a $12.4 million public offering that considerably strengthens our balance sheet and demonstrates confidence in our business prospects". He mentioned that the addition of Mr. Nader Kameli as COO of the Neurobionix business unit is strengthening Victhom's expertise in the high-growth Neuromodulation industry. He also added that Dr. Guy Chamberland, Vice President, Clinical and Regulatory Affairs, has left the Company but will remain involved with Victhom as a consultant on a part-time basis.

First Quarter Results

For the three-month period ended on March 31, 2007, the Company recorded revenues of $560,235 compared with $521,516 for the same period in 2006, representing an increase of $38,719 or 7.4%. The revenue increase compared to last year is attributable to the growth in nonrefundable advance royalty payments from our partner in the orthotics and prosthetics market. R&D expenses, before tax credits and grants, amounted to $1,984,179 for the three-month period ended on March 31, 2007, compared with $2,034,493 for the same period in 2006, representing a decrease of $50,314 or 2.5%. The decrease in R&D expenses is the result of the refocusing of the Neurobionix division R&D activities announced in January 2007, which resulted in a reduction in the number of employees. G&A expenses, net of non-cash stock-based compensation charges of $30,366, for the threemonth period ended on March 31, 2007, amounted to $603,977 compared with $807,928 for the same period in 2006, a decrease of $203,951 or 25%. The decrease is mainly due to a staff reduction in administrative functions and lower professional fees. Consolidated net loss for the quarter ended March 31, 2007, amounted to $2,254,308 compared to $2,757,567 for the same period in 2006, a decrease of $503,259 or 18%. The net loss, net of non-cash charges of $825,473, for the three-month period ended March 31, 2007, amounted to $1,428,835 compared to a net loss, net of non-cash charges of $905,461, for the same period in 2006, which amounted to $1,852,106, a decrease of $423,271 or 23%. The decrease in net loss, net of non-cash charges, is mainly the result of the lower development costs and G&A costs following the refocusing of R&D activities announced in January.

Financial Situation

At March 31, 2007, the Company had cash and cash equivalents position of $17 million compared to $6.5 million as at December 31, 2006. The increase was mainly due to the issuance of shares in the financing completed in March for gross proceeds of $12.4 million. The Company believes that with its current financial resources it will have sufficient liquidity to support its cash flow requirements for at least the next 12 months. On March 31, 2007, the number of common shares outstanding totaled 87,922,263 while 4,241,876 options were granted under the stock option plan and 25,964,942 share purchase warrants are in circulation pursuant to past unit offerings. The outstanding options and share purchase warrants are exercisable respectively at a weighted average exercise price of $0.98 and $0.76 per share.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix business unit focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix business unit develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics (or "O&P") market. Victhom's technologies and products are supported by a broad suite of intellectual property, including a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks, worldwide. Victhom has established a comprehensive process to ensure the protection of its intellectual property, pursuing filings for relevant discoveries and improvements.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

- 30 -

Source: Victhom Human Bionics Inc.

For more information: Normand Rivard

Vice President & CFO

Victhom Human Bionics Inc.

Tel.: (418) 872-5665, ext. 103

Fax: (418) 872-6926

normand.rivard@victhom.com

www.victhom.com

]]> Victhom discloses first quarter 2007 financial results 2007/05/11 Victhom appoints Mr. Nader Kameli as Chief Operating Officer of its neuromodulation business unit http://www.victhom.com/en/nouvelle.php?id=91 QUEBEC, April 17 - Victhom Human Bionics Inc. ("Victhom") (TSX: VHB) announces that Mr. Nader Kameli is joining the Company today as Chief Operating Officer of the Neurobionix business unit of Victhom which is responsible for the development and commercialization of its neuromodulation products."We are very pleased to welcome Mr. Nader Kameli to Victhom. With extensive and successful experience at high-profile medical device companies such as Guidant and Boston Scientific, Mr. Kameli brings not only a wealth of experience in product development, but also a keen understanding of the technical challenges and commercial opportunities in the high-growth Neuromodulation industry", stated Mr. Benoit Huet, President and CEO of Victhom. "Nader has the perfect mix of credentials and experience to drive the development and to harness the great potential of our Neurobionix business unit", Huet added. He also mentioned that the arrival of Mr. Kameli will allow Mr. Stéphane Bédard to focus on the orthotic and prosthetic business unit of Victhom.Mr. Kameli joins Victhom after eleven years of service at Guidant, now a Boston Scientific company. At the Cardiac Rhythm Management unit of Boston Scientific, he worked for six years managing product development, with a focus on implantable devices, and the last four years as the Group Manager of Business Development, identifying and utilizing external opportunities to accelerate internal development and to complement internal know-how. In this position, he managed the group involved in early- to late-stage engagements with outside entities including mergers and acquisitions, joint ventures, in-licensing, out-licensing and equity investments. Mr. Kameli has over twenty-five years of experience in safety-critical product development and covering product design, quality assurance, project management and business development. He has worked in large companies such as United Technologies and Boston Scientific as well as smaller companies such as Corometrics Medical Systems and Better Packages. Mr. Kameli's educational background is in electrical engineering and computer science, with emphasis in artificial intelligence, neuroscience and business administration.About VicthomVicthom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix business unit focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix business unit develops biomechatronic products to support or replace peripheral limbs in what is known as orthotics and prosthetics markets. Victhom's technologies and products are supported by a broad suite of intellectual property, including a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks, worldwide. Victhom has established a comprehensive process to ensure the protection of its intellectual property, pursuing filings for relevant discoveries andimprovements. For further information: Victhom Human Bionics Inc.: Benoit Huet,President and CEO, (418) 872-5665 ext. 103, Fax: (418) 872-6926,benoit.huet@victhom.com, www.victhom.com; Media Relations: Frédéric Tremblay,HKDP Communications and Public Affairs, (514) 395-0375, ext. 234,ftremblay@hkdp.qc.ca; Source: Victhom Human Bionics Inc. QUEBEC, April 17 - Victhom Human Bionics Inc. ("Victhom") (TSX: VHB) announces that Mr. Nader Kameli is joining the Company today as Chief Operating Officer of the Neurobionix business unit of Victhom which is responsible for the development and commercialization of its neuromodulation products.

"We are very pleased to welcome Mr. Nader Kameli to Victhom. With extensive and successful experience at high-profile medical device companies such as Guidant and Boston Scientific, Mr. Kameli brings not only a wealth of experience in product development, but also a keen understanding of the technical challenges and commercial opportunities in the high-growth Neuromodulation industry", stated Mr. Benoit Huet, President and CEO of Victhom. "Nader has the perfect mix of credentials and experience to drive the development and to harness the great potential of our Neurobionix business unit", Huet added. He also mentioned that the arrival of Mr. Kameli will allow Mr. Stéphane Bédard to focus on the orthotic and prosthetic business unit of Victhom.

Mr. Kameli joins Victhom after eleven years of service at Guidant, now a Boston Scientific company. At the Cardiac Rhythm Management unit of Boston Scientific, he worked for six years managing product development, with a focus on implantable devices, and the last four years as the Group Manager of Business Development, identifying and utilizing external opportunities to accelerate internal development and to complement internal know-how. In this position, he managed the group involved in early- to late-stage engagements with outside entities including mergers and acquisitions, joint ventures, in-licensing, out-licensing and equity investments. Mr. Kameli has over twenty-five years of experience in safety-critical product development and covering product design, quality assurance, project management and business development. He has worked in large companies such as United Technologies and Boston Scientific as well as smaller companies such as Corometrics Medical Systems and Better Packages. Mr. Kameli's educational background is in electrical engineering and computer science, with emphasis in artificial intelligence, neuroscience and business administration.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix business unit focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix business unit develops biomechatronic products to support or replace peripheral limbs in what is known as orthotics and prosthetics markets.

Victhom's technologies and products are supported by a broad suite of intellectual property, including a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks, worldwide. Victhom has established a comprehensive process to ensure the protection of its intellectual property, pursuing filings for relevant discoveries and
improvements.

 

For further information:

Victhom Human Bionics Inc.: Benoit Huet,
President and CEO, (418) 872-5665 ext. 103, Fax: (418) 872-6926,
benoit.huet@victhom.com, www.victhom.com;

Media Relations: Frédéric Tremblay,
HKDP Communications and Public Affairs, (514) 395-0375, ext. 234,
ftremblay@hkdp.qc.ca;

Source: Victhom Human Bionics Inc.

]]> Victhom appoints Mr. Nader Kameli as Chief Operating Officer of its neuromodulation business unit 2007/04/17 Mr. Martin Leblanc becomes a director of Victhom http://www.victhom.com/en/nouvelle.php?id=90 Quebec (Canada), April 4, 2007 �??Victhom Human Bionics Inc., (�??Victhom�??) (TSX: VHB), announced today that Mr. Martin LeBlanc had joined its Board of Directors on March 23rd, 2007. �??Mr. LeBlanc will be bringing exceptional expertise to Victhom, and his experience will be especially relevant and useful for the future development of the Company�?? said Mr. Daniel Johnson, Chairman of the Board.Mr. LeBlanc is currently President of Caprion Proteomics. He was a Co-founder of Caprion Pharmaceuticals and served as its Chief Operating Officer from 2000 to 2007. Prior to that, he was successively a management consultant with McKinsey & Company, VP of Sales & Marketing at Advanced Bioconcept Ltd. and its General Manager after its acquisition by NEN Life Sciences (now Perkin-Elmer). He is also Co-chair of Montreal In-Vivo, and a member of the Board of Directors of the Atlantic Cancer Research Institute. Mr. LeBlanc holds a B.Sc.Soc. from the University of Moncton (N.-B.) and an M.A. from Oxford University where he was a Rhodes Scholar.Mr. André Monette has decided not to seek re-election for the position of Director at the next annual meeting, and he has chosen to leave the Board of Directors on April 2, 2007.About VicthomVicthom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.-30-Website : www.victhom.comSource: Victhom Human Bionics Inc.For more information:Mr. Daniel JohnsonChairman of the BoardTel.: (514) 397-4161Fax: (514) 875-6246 djohnson@mccarthy.caMedia RelationsFrédéric TremblayHKDP Communications and Public AffairsTel.: (514) 395-0375, ext. 234ftremblay@hkdp.qc.ca Quebec (Canada), April 4, 2007 �??Victhom Human Bionics Inc., (�??Victhom�??) (TSX: VHB), announced today that Mr. Martin LeBlanc had joined its Board of Directors on March 23rd, 2007. �??Mr. LeBlanc will be bringing exceptional expertise to Victhom, and his experience will be especially relevant and useful for the future development of the Company�?? said Mr. Daniel Johnson, Chairman of the Board.

Mr. LeBlanc is currently President of Caprion Proteomics. He was a Co-founder of Caprion Pharmaceuticals and served as its Chief Operating Officer from 2000 to 2007. Prior to that, he was successively a management consultant with McKinsey & Company, VP of Sales & Marketing at Advanced Bioconcept Ltd. and its General Manager after its acquisition by NEN Life Sciences (now Perkin-Elmer). He is also Co-chair of Montreal In-Vivo, and a member of the Board of Directors of the Atlantic Cancer Research Institute. Mr. LeBlanc holds a B.Sc.Soc. from the University of Moncton (N.-B.) and an M.A. from Oxford University where he was a Rhodes Scholar.

Mr. André Monette has decided not to seek re-election for the position of Director at the next annual meeting, and he has chosen to leave the Board of Directors on April 2, 2007.

About Victhom

Victhom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.

Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.

-30-

Website : www.victhom.com

Source: Victhom Human Bionics Inc.

For more information:

Mr. Daniel Johnson
Chairman of the Board
Tel.: (514) 397-4161
Fax: (514) 875-6246
djohnson@mccarthy.ca

Media Relations

Frédéric Tremblay
HKDP Communications and Public Affairs
Tel.: (514) 395-0375, ext. 234
ftremblay@hkdp.qc.ca

]]> Mr. Martin Leblanc becomes a director of Victhom 2007/04/05 Victhom Human Bionics winner of a "Genesis" award http://www.victhom.com/en/nouvelle.php?id=89 Victhom�??s technological platform is awarded the Innovation trophyQuebec (Canada), April 3, 2007 �?? Victhom Human Bionics Inc. (�??Victhom�??) (TSX: VHB), is pleased to announce that it was the recipient of the Genesis award in the Innovation category, at the seventh edition of the Genesis Awards Gala which took place in Montreal on March 29.�??We are very proud of the recognition of the innovation brought about by Victhom products and technologies. This award provides all our employees with an additional encouragement to continue their work in order to commercialize innovative products that will improve the quality of life of patients with physical dysfunctions�??, stated Mr. Benoit Huet, the President and CEO of Victhom.About the Genesis Awards GalaStarted by BIOQuebec in 2001, the Genesis Awards Gala seeks to recognize Entrepreneurship, Innovation and Technology Transfer of Quebec companies and to honour individual pre-eminence among the personalities who have played a key role in the growth of Quebec�??s Life Sciences Industry.About VicthomVicthom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: Biotronix and Neurobionix.Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.-30-Website: www.victhom.comSource: Victhom Human Bionics Inc.For more information:Victhom Human Bionics Inc.Benoit Huet President and CEO Tel.: (418) 872-5665, ext. 103 Fax: (418) 872-6926 benoit.huet@victhom.comMedia Relations:Frédéric TremblayHKDP Communications and Public AffairsTel.: (514) 395-0375, ext. 234ftremblay@hkdp.qc.ca Victhom�??s technological platform is awarded the Innovation trophy

Quebec (Canada), April 3, 2007 �?? Victhom Human Bionics Inc. (�??Victhom�??) (TSX: VHB), is pleased to announce that it was the recipient of the Genesis award in the Innovation category, at the seventh edition of the Genesis Awards Gala which took place in Montreal on March 29.

�??We are very proud of the recognition of the innovation brought about by Victhom products and technologies. This award provides all our employees with an additional encouragement to continue their work in order to commercialize innovative products that will improve the quality of life of patients with physical dysfunctions�??, stated Mr. Benoit Huet, the President and CEO of Victhom.

About the Genesis Awards Gala

Started by BIOQuebec in 2001, the Genesis Awards Gala seeks to recognize Entrepreneurship, Innovation and Technology Transfer of Quebec companies and to honour individual pre-eminence among the personalities who have played a key role in the growth of Quebec�??s Life Sciences Industry.

About Victhom

Victhom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: Biotronix and Neurobionix.

Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.

-30-

Website: www.victhom.com

Source: Victhom Human Bionics Inc.

For more information:

Victhom Human Bionics Inc.
Benoit Huet President and CEO
Tel.: (418) 872-5665, ext. 103
Fax: (418) 872-6926
benoit.huet@victhom.com

Media Relations:

Frédéric Tremblay
HKDP Communications and Public Affairs
Tel.: (514) 395-0375, ext. 234
ftremblay@hkdp.qc.ca

]]> Victhom Human Bionics winner of a "Genesis" award 2007/04/03 Victhom discloses annual and fourth quarter 2006 results http://www.victhom.com/en/nouvelle.php?id=88 Quebec (Quebec), March 26, 2007 �?? Victhom Human Bionics Inc. "Victhom" (TSX: VHB) today announced results for the fourth quarter and fiscal year ended on December 31, 2006. Mr. Benoit Huet, President and CEO of Victhom said, �??During 2006, Victhom reached very important milestones with the worldwide commercial launch of the Power Knee by our partner Ossur and the authorization by Health Canada of the clinical trial for our first neuromodulation product, the Neurostep. We are satisfied with the progress achieved in both our Biotronix and Neurobionix business units resulting from a better focus of our R&D activities.�??Annual 2006 and Fourth Quarter ResultsFor the year ended on December 31, 2006, the Company recorded revenues of $3.2 million compared with $4.2 million in 2005. For the fourth quarter, the Company recorded revenues of $1.2 million compared with $1.5 million in 2005. The revenue decrease compared to last year is attributable to payments received in 2005 on a non-recurring collaborative work contract with a medical device company. This factor was partially offset by the growth, compared to last year, in non-refundable advance royalty payments from our partner in the Orthotics and Prosthetics market.Research and Development (�??R&D�??) expenses, before tax credits and grants, amounted to $8.4 million in 2006 compared with $6.2 million in 2005, an increase of 35%. For the fourth quarter 2006, the R&D expenses, before tax credits and grants, amounted to $2.2 million compared with $1.6 million in 2005, an increase of 38%. The increase in R&D expenses is the result of higher development costs directly linked to the Company�??s product rollout strategy in the neuromodulation market. Also, in 2005, a portion of the R&D expenses was allocated to the cost of revenues to account for the work performed on a collaborative work contract with a medical device company.General and administrative (�??G&A�??) expenses, net of non-cash stock based compensation charge of $0.4 million, for the year ended on December 31, 2006 amounted to $3.0 million compared with $3.0 million for the same period in 2005. For the fourth quarter 2006, the G&A expenses, net of non-cash stock based compensation charge, amounted to $0.7 million compared with $0.8 million for the same period in 2005, a decrease of 14% mainly due to lower professional fees.Consolidated net loss for the year ended on December 31, 2006, amounted to $10.1 million compared to $8.2 million for the same period in 2005, an increase of 24%. Consolidated net loss, net of non-cash charges of $3.4 million for the year ended on December 31, 2006, amounted to $6.7 million compared to a net loss, net of non-cash charges of $2.4 million for the same period in 2005, which amounted to $5.8 million, an increase of 16%. Consolidated net loss, net of non-cash charges of $0.7 million, for the quarter ended on December 31, 2006, amounted to $1.9 million compared to a net loss, net of non-cash charges of $0.2 million for the fourth quarter in 2005, which amounted to $1.4 million, an increase of 33%. The increase in net loss, net of non-cash charges, is mainly the result of higher development costs directly linked to the Company�??s product rollout strategy in the neuromodulation market.On December 31, 2006, the Company had cash and cash equivalents position of $6.5 million. The Company believes that with its current and planned financial resources, including the gross proceeds of $12.4M from the financing announced on March 16, 2007, it will have sufficient liquidity to support its cash flow requirements for at least the next 12 months.On December 31, 2006, the number of common shares outstanding totaled 52,592,440 while 4,575,729 options were granted under the stock option plan and 7,613,511 share purchase warrants are in circulation pursuant to past unit offerings. The outstanding options and share purchase warrants are exercisable respectively at a weighted average price of $0.98 and $1.58 per share.About VicthomVicthom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: Biotronix and Neurobionix.Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.FORWARD-LOOKING STATEMENTSSome of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom�??s actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom�??s statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.- 30 -Website: www.victhom.comSource: Victhom Human Bionics Inc.For more information:Victhom Human Bionics Inc.Benoit HuetPresident and CEOTel. : (418) 872-5665 ext. 103Fax : (418) 872-6926benoit.huet@victhom.comMedia RelationsFrédéric TremblayHKDP Communications and Public AffairsTél. : (514) 395-0375 ext. 234ftremblay@hkdp.qc.ca Quebec (Quebec), March 26, 2007 �?? Victhom Human Bionics Inc. "Victhom" (TSX: VHB) today announced results for the fourth quarter and fiscal year ended on December 31, 2006. Mr. Benoit Huet, President and CEO of Victhom said, �??During 2006, Victhom reached very important milestones with the worldwide commercial launch of the Power Knee by our partner Ossur and the authorization by Health Canada of the clinical trial for our first neuromodulation product, the Neurostep. We are satisfied with the progress achieved in both our Biotronix and Neurobionix business units resulting from a better focus of our R&D activities.�??

Annual 2006 and Fourth Quarter Results

For the year ended on December 31, 2006, the Company recorded revenues of $3.2 million compared with $4.2 million in 2005. For the fourth quarter, the Company recorded revenues of $1.2 million compared with $1.5 million in 2005. The revenue decrease compared to last year is attributable to payments received in 2005 on a non-recurring collaborative work contract with a medical device company. This factor was partially offset by the growth, compared to last year, in non-refundable advance royalty payments from our partner in the Orthotics and Prosthetics market.

Research and Development (�??R&D�??) expenses, before tax credits and grants, amounted to $8.4 million in 2006 compared with $6.2 million in 2005, an increase of 35%. For the fourth quarter 2006, the R&D expenses, before tax credits and grants, amounted to $2.2 million compared with $1.6 million in 2005, an increase of 38%. The increase in R&D expenses is the result of higher development costs directly linked to the Company�??s product rollout strategy in the neuromodulation market. Also, in 2005, a portion of the R&D expenses was allocated to the cost of revenues to account for the work performed on a collaborative work contract with a medical device company.

General and administrative (�??G&A�??) expenses, net of non-cash stock based compensation charge of $0.4 million, for the year ended on December 31, 2006 amounted to $3.0 million compared with $3.0 million for the same period in 2005. For the fourth quarter 2006, the G&A expenses, net of non-cash stock based compensation charge, amounted to $0.7 million compared with $0.8 million for the same period in 2005, a decrease of 14% mainly due to lower professional fees.

Consolidated net loss for the year ended on December 31, 2006, amounted to $10.1 million compared to $8.2 million for the same period in 2005, an increase of 24%. Consolidated net loss, net of non-cash charges of $3.4 million for the year ended on December 31, 2006, amounted to $6.7 million compared to a net loss, net of non-cash charges of $2.4 million for the same period in 2005, which amounted to $5.8 million, an increase of 16%. Consolidated net loss, net of non-cash charges of $0.7 million, for the quarter ended on December 31, 2006, amounted to $1.9 million compared to a net loss, net of non-cash charges of $0.2 million for the fourth quarter in 2005, which amounted to $1.4 million, an increase of 33%. The increase in net loss, net of non-cash charges, is mainly the result of higher development costs directly linked to the Company�??s product rollout strategy in the neuromodulation market.

On December 31, 2006, the Company had cash and cash equivalents position of $6.5 million. The Company believes that with its current and planned financial resources, including the gross proceeds of $12.4M from the financing announced on March 16, 2007, it will have sufficient liquidity to support its cash flow requirements for at least the next 12 months.

On December 31, 2006, the number of common shares outstanding totaled 52,592,440 while 4,575,729 options were granted under the stock option plan and 7,613,511 share purchase warrants are in circulation pursuant to past unit offerings. The outstanding options and share purchase warrants are exercisable respectively at a weighted average price of $0.98 and $1.58 per share.

About Victhom

Victhom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: Biotronix and Neurobionix.

Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom�??s actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom�??s statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

- 30 -

Website: www.victhom.com

Source: Victhom Human Bionics Inc.

For more information:

Victhom Human Bionics Inc.
Benoit Huet
President and CEO
Tel. : (418) 872-5665 ext. 103
Fax : (418) 872-6926
benoit.huet@victhom.com

Media Relations

Frédéric Tremblay
HKDP Communications and Public Affairs
Tél. : (514) 395-0375 ext. 234
ftremblay@hkdp.qc.ca

]]> Victhom discloses annual and fourth quarter 2006 results 2007/03/26 Victhom Human Bionics Inc. completes a financing of CDN$12,363,105 http://www.victhom.com/en/nouvelle.php?id=87 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.Québec (Canada), March 16, 2007 �?? Victhom Human Bionics Inc. (�??Victhom�??) (TSX: VHB) is pleased to announce that it has completed a public offering by way of short form prospectus of 35,323,156 units at a price of $0.35 per unit for a total gross proceeds of $12,363,104.60. Each unit consists of one common share of Victhom and one half of one common share purchase warrant. Each whole share purchase warrant entitles the holder thereof to purchase one common share at a price of $0.45 over a three-year period from closing. The offering was made through a syndicate of agents co-led by Dundee Securities Corporation and Desjardins Securities Inc., and including Loewen, Ondaatje, McCutcheon Limited.Victhom intends to use the net proceeds of the offering for the completion of its ongoing clinical trials on the NeurostepTM in order to register the product with the European and American health authorities and for the completion of its development activities to adapt the NeurostepTM CLS Neuromodulator to target high potential new indications that could include, among others, sleep apnea, obesity and chronic pain.THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL.About VicthomVicthom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.FORWARD-LOOKING STATEMENTSSome of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom�??s actual results, performance or achievements to be materially different from those expressed or implied by any of the Victhom�??s statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.Website: www.victhom.comSource: Victhom Human Bionics Inc.For more information:Victhom Human Bionics Inc. Benoit Huet President and CEO Tel. : (418) 872-5665 ext. 103 Fax : (418) 872-6926 benoit.huet@victhom.comMedia RelationsFrédéric Tremblay HKDP Communications and Public Affairs Tél. : (514) 395-0375 ext. 234 ftremblay@hkdp.qc.ca THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Québec (Canada), March 16, 2007 �?? Victhom Human Bionics Inc. (�??Victhom�??) (TSX: VHB) is pleased to announce that it has completed a public offering by way of short form prospectus of 35,323,156 units at a price of $0.35 per unit for a total gross proceeds of $12,363,104.60. Each unit consists of one common share of Victhom and one half of one common share purchase warrant. Each whole share purchase warrant entitles the holder thereof to purchase one common share at a price of $0.45 over a three-year period from closing. The offering was made through a syndicate of agents co-led by Dundee Securities Corporation and Desjardins Securities Inc., and including Loewen, Ondaatje, McCutcheon Limited.

Victhom intends to use the net proceeds of the offering for the completion of its ongoing clinical trials on the NeurostepTM in order to register the product with the European and American health authorities and for the completion of its development activities to adapt the NeurostepTM CLS Neuromodulator to target high potential new indications that could include, among others, sleep apnea, obesity and chronic pain.

THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL.

About Victhom

Victhom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.

Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom�??s actual results, performance or achievements to be materially different from those expressed or implied by any of the Victhom�??s statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

Website: www.victhom.com

Source: Victhom Human Bionics Inc.

For more information:

Victhom Human Bionics Inc.
Benoit Huet
President and CEO
Tel. : (418) 872-5665 ext. 103
Fax : (418) 872-6926
benoit.huet@victhom.com

Media Relations

Frédéric Tremblay
HKDP Communications and Public Affairs
Tél. : (514) 395-0375 ext. 234
ftremblay@hkdp.qc.ca

]]> Victhom Human Bionics Inc. completes a financing of CDN$12,363,105 2007/03/16 Victhom Human Bionics Inc. announces the filling of a final prospectus. http://www.victhom.com/en/nouvelle.php?id=86 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.Québec (Canada), March 9, 2007 �?? Victhom Human Bionics Inc. (�??Victhom�??) (TSX: VHB) is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in the provinces of British Columbia, Alberta, Ontario and Québec pursuant to which Victhom proposes to complete a public offering of units at a price of $0.35 per unit for a minimum amount of $10 million and a maximum of $15 million. Each unit will consist of one common share of Victhom and one half of one common share purchase warrant. Each whole share purchase warrant entitles the holder thereof to purchase one common share at a price of $0.45 at any time prior to 5:00 p.m. (Montreal time) on the date that is 36 months following the closing of the offering.The offering is being made through a syndicate of agents co-led by Dundee Securities Corporation and Desjardins Securities Inc., and including Loewen, Ondaatje, McCutcheon Limited (collectively, the �??Agents�??). The Agents will receive a fee of $0.021 per unit other than with respect to the subscription from certain predetermined investors for up to $8,000,000 with respect to which the fee will be $0.007 per unit. In addition to the Agents�?? fee mentioned above, the Agents will also be granted compensation options (the �??Agents�?? Warrants�??) entitling the holders thereof to purchase a number of common shares of Victhom equal to 6% of the units sold under this offering other than with respect to subscribers from certain predetermined investors with respect to which the number of Agents�?? Warrants will be equal to 2% of the units subscribed by these predetermined investors. Each Agents�?? Warrant will grant its holder the right to acquire one common share of Victhom at a price of $0.35 for a period of 36 months following the closing of the offering.Victhom intends to use the net proceeds of the offering for the completion of its ongoing clinical trials on the NeurostepTM in order to register the product with the European and American health authorities and for the completion of its development activities to adapt the NeurostepTM CLS Neuromodulator to target high potential new indications that could include, among others, sleep apnea, obesity and chronic pain.THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL.About VicthomVicthom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.FORWARD-LOOKING STATEMENTSSome of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom�??s actual results, performance or achievements to be materially different from those expressed or implied by any of the Victhom�??s statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.Website: www.victhom.comSource: Victhom Human Bionics Inc.For more information:Victhom Human Bionics Inc.Benoit HuetPresident and CEOTel. : (418) 872-5665 ext. 103Fax : (418) 872-6926benoit.huet@victhom.comMedia RelationsFrédéric TremblayHKDP Communications and Public AffairsTél. : (514) 395-0375 ext. 234ftremblay@hkdp.qc.ca THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Québec (Canada), March 9, 2007 �?? Victhom Human Bionics Inc. (�??Victhom�??) (TSX: VHB) is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in the provinces of British Columbia, Alberta, Ontario and Québec pursuant to which Victhom proposes to complete a public offering of units at a price of $0.35 per unit for a minimum amount of $10 million and a maximum of $15 million. Each unit will consist of one common share of Victhom and one half of one common share purchase warrant. Each whole share purchase warrant entitles the holder thereof to purchase one common share at a price of $0.45 at any time prior to 5:00 p.m. (Montreal time) on the date that is 36 months following the closing of the offering.

The offering is being made through a syndicate of agents co-led by Dundee Securities Corporation and Desjardins Securities Inc., and including Loewen, Ondaatje, McCutcheon Limited (collectively, the �??Agents�??). The Agents will receive a fee of $0.021 per unit other than with respect to the subscription from certain predetermined investors for up to $8,000,000 with respect to which the fee will be $0.007 per unit. In addition to the Agents�?? fee mentioned above, the Agents will also be granted compensation options (the �??Agents�?? Warrants�??) entitling the holders thereof to purchase a number of common shares of Victhom equal to 6% of the units sold under this offering other than with respect to subscribers from certain predetermined investors with respect to which the number of Agents�?? Warrants will be equal to 2% of the units subscribed by these predetermined investors. Each Agents�?? Warrant will grant its holder the right to acquire one common share of Victhom at a price of $0.35 for a period of 36 months following the closing of the offering.

Victhom intends to use the net proceeds of the offering for the completion of its ongoing clinical trials on the NeurostepTM in order to register the product with the European and American health authorities and for the completion of its development activities to adapt the NeurostepTM CLS Neuromodulator to target high potential new indications that could include, among others, sleep apnea, obesity and chronic pain.

THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL.

About Victhom

Victhom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.

Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom�??s actual results, performance or achievements to be materially different from those expressed or implied by any of the Victhom�??s statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

Website: www.victhom.com

Source: Victhom Human Bionics Inc.

For more information:

Victhom Human Bionics Inc.
Benoit Huet
President and CEO
Tel. : (418) 872-5665 ext. 103
Fax : (418) 872-6926
benoit.huet@victhom.com

Media Relations

Frédéric Tremblay
HKDP Communications and Public Affairs
Tél. : (514) 395-0375 ext. 234
ftremblay@hkdp.qc.ca

]]> Victhom Human Bionics Inc. announces the filling of a final prospectus. 2007/03/09 Victhom Human Bionics announces the filing of a preliminary prospectus. http://www.victhom.com/en/nouvelle.php?id=85 THIS PRESS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.Quebec (Canada), January 29, 2007 �?? Victhom Human Bionics Inc. (�??Victhom�??) (TSX: VHB) is pleased to announce that it has filed a preliminary short-form prospectus with the securities regulatory authorities in the provinces of British Columbia, Alberta, Ontario and Quebec pursuant to which Victhom proposes to complete a public offering of units for a minimum amount of $10 million. The offering is being made through a syndicate of agents co-led by Dundee Securities Corporation and Desjardins Securities Inc., and including Loewen, Ondaatje, McCutcheon Limited. Each unit will consist of one common share of Victhom and one half of one common share purchase warrant. The price of the units and the final terms of the warrants will be agreed upon between the Agents and Victhom prior to filing of the final prospectus.Victhom intends to use the net proceeds of the offering for the completion of its ongoing clinical trials on the Neurostep�?� in order to register the product with the European and American Health Authorities and for the completion of its development activities to adapt the Neurostep�?� CLS Neuromodulator to target high-potential new indications that could include, among others, sleep apnea, obesity and chronic pain.THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL.About VicthomVicthom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.FORWARD-LOOKING STATEMENTSSome of the statements made herein may constitute forward-looking statements. These statements relate to future events or future financial performance of Victhom and involve known and unknown risks, uncertainties and other factors that may cause Victhom�??s actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom�??s statements. Actual events or results may differ materially. Victhom disclaims any intention, and assumes no obligation, to update these forward-looking statements.Website: www.victhom.comSource: Victhom Human Bionics Inc.For more information:Victhom Human Bionics Inc.Benoit HuetPresident and CEOTel.: (418) 872-5665 ext. 103Fax: (418) 872-6926benoit.huet@victhom.comMedia RelationsFrédéric TremblayHKDP Communications and Public AffairsTel.: (514) 395-0375, ext. 234ftremblay@hkdp.qc.ca THIS PRESS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

Quebec (Canada), January 29, 2007 �?? Victhom Human Bionics Inc. (�??Victhom�??) (TSX: VHB) is pleased to announce that it has filed a preliminary short-form prospectus with the securities regulatory authorities in the provinces of British Columbia, Alberta, Ontario and Quebec pursuant to which Victhom proposes to complete a public offering of units for a minimum amount of $10 million. The offering is being made through a syndicate of agents co-led by Dundee Securities Corporation and Desjardins Securities Inc., and including Loewen, Ondaatje, McCutcheon Limited. Each unit will consist of one common share of Victhom and one half of one common share purchase warrant. The price of the units and the final terms of the warrants will be agreed upon between the Agents and Victhom prior to filing of the final prospectus.

Victhom intends to use the net proceeds of the offering for the completion of its ongoing clinical trials on the Neurostep�?� in order to register the product with the European and American Health Authorities and for the completion of its development activities to adapt the Neurostep�?� CLS Neuromodulator to target high-potential new indications that could include, among others, sleep apnea, obesity and chronic pain.

THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL.

About Victhom

Victhom researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. Victhom has two business units: BioTronix and NeuroBionix.

Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. Victhom has established an ongoing process to ensure the protection of its intellectual property and to pursue filings for any discovery or improvements to its technologies.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or future financial performance of Victhom and involve known and unknown risks, uncertainties and other factors that may cause Victhom�??s actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom�??s statements. Actual events or results may differ materially. Victhom disclaims any intention, and assumes no obligation, to update these forward-looking statements.

Website: www.victhom.com

Source: Victhom Human Bionics Inc.

For more information:

Victhom Human Bionics Inc.
Benoit Huet
President and CEO
Tel.: (418) 872-5665 ext. 103
Fax: (418) 872-6926
benoit.huet@victhom.com

Media Relations

Frédéric Tremblay
HKDP Communications and Public Affairs
Tel.: (514) 395-0375, ext. 234
ftremblay@hkdp.qc.ca

]]> Victhom Human Bionics announces the filing of a preliminary prospectus. 2007/01/30 Victhom Human Bionics announces the start of patient enrolment for its NEUROSTEP�? clinical trial http://www.victhom.com/en/nouvelle.php?id=84 REFOCUSES ITS R&D ACTIVITIESQuebec, Canada, January 16, 2007 - Victhom Human Bionics Inc. (TSX: VHB) announces today that it received approval from the Ethics Review Board of the rehabilitation center where its clinical trial on gait disorders will be held. The Company received its Investigational Testing Authorization in December 2006 from Health Canada. The Neurostep�?� is designed to treat, through neuromodulation, gait disorders (e.g., foot drop) secondary to a lesion of the central nervous system caused by conditions such as stroke or multiple sclerosis. Over one million patients in the U.S. and in Europe could benefit from this product.Dr. Guy Chamberland, M.Sc., Ph.D., Vice President Clinical and Regulatory Affairs, stated that the Company was initiating patient enrolment for its clinical trial this month. This will be the world�??s first human trial of a fully implantable Closed-Loop System (sensing and stimulation) for the peripheral nervous system.Mr. Stéphane Bédard, Executive Vice President and COO, stated that in light of the above, the Company is focusing the R&D activities of its NeuroBionix division on the clinical development of the Neurostep�?� and aggressively pursuing the development of a closed-loop neuromodulator (neurosensing and neurostimulation of the peripheral nervous system) for the treatment of pathologies such as sleep apnea, obesity and chronic pain. Victhom also announced it has put on hold the preclinical development of a bladder neuroprosthesis for patients with spinal cord injury. This decision was made after a normal course review of the entire portfolio of programs under development and to optimize R&D expenses.As part of the refocusing of its R&D activities, Victhom has reduced the number of its employees. This reduction will result in a non-material and non-recurring charge for the Company. This will also allow Victhom to conduct its clinical activities in 2007 with the required resources.About VicthomVicthom Human Bionics (TSX: VHB) researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. The Company has two research units: BioTronix and NeuroBionix.Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. The Company has established an ongoing process to ensure the protection of its intellectual property and to pursue new filings.* Forward-looking statements contained in this press release involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.- 30 -Website: www.victhom.comSource: Victhom Human Bionics Inc.For more information:Victhom Human BionicsMr. Benoit HuetPresident and CEOTel.: (418) 872-5665, ext. 103Fax: (418) 872-6926benoit.huet@victhom.comMedia RelationsFrédéric TremblayHKDP Communications and Public AffairsTel.: (514) 395-0375, ext. 234ftremblay@hkdp.qc.ca REFOCUSES ITS R&D ACTIVITIES

Quebec, Canada, January 16, 2007 - Victhom Human Bionics Inc. (TSX: VHB) announces today that it received approval from the Ethics Review Board of the rehabilitation center where its clinical trial on gait disorders will be held. The Company received its Investigational Testing Authorization in December 2006 from Health Canada. The Neurostep�?� is designed to treat, through neuromodulation, gait disorders (e.g., foot drop) secondary to a lesion of the central nervous system caused by conditions such as stroke or multiple sclerosis. Over one million patients in the U.S. and in Europe could benefit from this product.

Dr. Guy Chamberland, M.Sc., Ph.D., Vice President Clinical and Regulatory Affairs, stated that the Company was initiating patient enrolment for its clinical trial this month. This will be the world�??s first human trial of a fully implantable Closed-Loop System (sensing and stimulation) for the peripheral nervous system.

Mr. Stéphane Bédard, Executive Vice President and COO, stated that in light of the above, the Company is focusing the R&D activities of its NeuroBionix division on the clinical development of the Neurostep�?� and aggressively pursuing the development of a closed-loop neuromodulator (neurosensing and neurostimulation of the peripheral nervous system) for the treatment of pathologies such as sleep apnea, obesity and chronic pain. Victhom also announced it has put on hold the preclinical development of a bladder neuroprosthesis for patients with spinal cord injury. This decision was made after a normal course review of the entire portfolio of programs under development and to optimize R&D expenses.

As part of the refocusing of its R&D activities, Victhom has reduced the number of its employees. This reduction will result in a non-material and non-recurring charge for the Company. This will also allow Victhom to conduct its clinical activities in 2007 with the required resources.

About Victhom

Victhom Human Bionics (TSX: VHB) researches, develops and delivers bionic devices that treat a variety of physiological dysfunctions. The Company has two research units: BioTronix and NeuroBionix.

Victhom manages a portfolio of 37 granted and 82 pending patents filed in various countries and 13 registered trademarks worldwide. The Company has established an ongoing process to ensure the protection of its intellectual property and to pursue new filings.

* Forward-looking statements contained in this press release involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

- 30 -

Website: www.victhom.com

Source: Victhom Human Bionics Inc.

For more information:

Victhom Human Bionics
Mr. Benoit Huet
President and CEO
Tel.: (418) 872-5665, ext. 103
Fax: (418) 872-6926
benoit.huet@victhom.com

Media Relations

Frédéric Tremblay
HKDP Communications and Public Affairs
Tel.: (514) 395-0375, ext. 234
ftremblay@hkdp.qc.ca

]]> Victhom Human Bionics announces the start of patient enrolment for its NEUROSTEP�? clinical trial 2007/01/16